60199-81-7

Basic information

• Product Name: 4-Bromooxanilic acid hydrazide
• Synonyms: 4-Bromooxanilic acid hydrazide
• CAS NO: 60199-81-7
• Molecular Weight: 258.074
• Mol File: 60199-81-7.mol

Chemical Properties

• CAS DataBase Reference: 4-Bromooxanilic acid hydrazide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Bromooxanilic acid hydrazide(60199-81-7)
• EPA Substance Registry System: 4-Bromooxanilic acid hydrazide(60199-81-7)

Safety Data

• Hazardous Substances Data: 60199-81-7(Hazardous Substances Data)

Upstream product

• 24451-15-8 ethyl N-p-bromophenyloxamate 
• 79354-51-1 4-bromooxanilic acid 
• 106-40-1 4-bromo-aniline 

Downstream Products

• 108098-07-3 3-[(4-Bromo-phenylaminooxalyl)-hydrazono]-2-oxo-2,3-dihydro-1H-indole-7-carboxylic acid 
• 1418013-12-3 C₂₀H₁₉BrN₄OS 
• 1418012-69-7 5-mercapto-4-phenyl-4H[1,2,4]triazole-3-carboxylic acid (4-bromo-phenyl)amide 

Relevant articles and documents

SYNTHESIS of NOVEL NITROGEN HETEROCYCLES BEARING BIOLOGICAL ACTIVE CARBOXAMIDE MOIETY AS POTENTIAL ANTITUMOR AGENTS

In the present study, synthesis of a simple series of nitrogen heterocycles containing N-(p-bromophenyl) carboxamide moiety, such as benzimidazole, benzoxazine, oxadiazole and triazole compounds, by using 4-bromo aniline and diethyl oxalate as a key start

NOVEL HETEROARYL COMPOUND, ENANTIOMER, DIASTEREOMER OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND ANTIVIRAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT

The present invention relates to a novel heteroaryl compound, an enantiomer, a diastereomer or a pharmaceutically acceptable salt thereof, and an antiviral composition comprising the same as an active ingredient. The novel compounds represented by formula (I) or formula (II) according to the present invention are remarkably superior in antiviral activity against an influenza virus, and furthermore, have low cytotoxicity and thus low adverse effects on a human body. Therefore, a pharmaceutical composition containing the same as an active ingredient can be effectively used for the prevention or treatment of diseases caused by an influenza virus infection.

Alkylsulfanyl-1,2,4-triazoles, a New Class of allosteric valosine containing protein inhibitors. Synthesis and structure-activity relationships

Valosine containing protein (VCP), also known as p97, is a member of AAA ATPase family that is involved in several biological processes and plays a central role in the ubiquitin-mediated degradation of misfolded proteins. VCP is an ubiquitously expressed, highly abundant protein and has been found overexpressed in many tumor types, sometimes associated with poor prognosis. In this respect, VCP has recently received a great deal of attention as a potential new target for cancer therapy. In this paper, the discovery and structure-activity relationships of alkylsulfanyl-1,2,4-triazoles, a new class of potent, allosteric VCP inhibitors, are described. Medicinal chemistry manipulation of compound 1, identified via HTS, led to the discovery of potent and selective inhibitors with submicromolar activity in cells and clear mechanism of action at consistent doses. This represents a first step toward a new class of potential anticancer agents.

Hydrazido functionalized 2-(2-hydroxyphenyl)-2H-benzotriazoles

Ultraviolet light stabilizers are chemically bound to anhydride containing polymers or copolymers. Polymeric stabilizers are prepared by the reaction of primary amino or hydrazido-substituted UV absorbers with some or all of the anhydride groups of the polymer or copolymer to form pendant stabilizer substituted imide or amic acid groups. The polymer bound stabilizers are not lost from the polymer system by volatilization, migration, or extraction, even at high temperature. The polymer stabilizers of this invention may be used as they are or as concentrates to stabilize other polymer systems.